- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03344133
Effect of Exercise Programme on Gut Microbiota, CVD Risk Factors and Appetite Regulation in Overweight Women
Effect of a 4-week Moderate Intensity Exercise Programme on Gut Microbiota, Cardiovascular Disease Risk Factors and Appetite Regulation in Overweight Women
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Study Design: This is a randomized controlled study with a parallel design. Healthy, sedentary females aged between 18-45 years old will be recruited by means of an advertisement leaflet and word of mouth. Eligible participants will be enrolled in the study and will be randomly allocated to either exercise intervention (EX) or control (C) groups. The EX group will participate in a 4-week exercise intervention and the C group will be asked to continue with habitual life style for 4 weeks. Before and after 4 weeks of the intervention, participants from both groups will be asked to conduct a submaximal exercise test and a 7-hour experimental trial during which blood samples will be collected and metabolic rate will measured before and after consumption of standardized breakfast and lunch. Prior to the first 7-hour trial, participants will be asked to record diet for 3 days and replicate this diet prior to the second 7-hour trial. During these 3 days participants will provide fresh stool samples. Participants allocated to control group will have the option to participate in exercise intervention. A subset of the participants will repeat a 7-hour experimental trial and provide fresh stool and urine sample after 7 days of detraining.
Methods:
Preliminary Health Check: Participants will undertake a health screening questionnaire on the day of recruitment. Participants will also need to fill in Physical Activity Readiness Questionnaire (PARQ). Only participants who answered "no" to all questions in PARQ will conduct the submaximal exercise test.
Anthropometry: All participants will have height, weight and waist circumference measured at baseline and 4 weeks after the intervention.
7-hour Experimental Trial: Participants will attend the metabolic suite (New Lister Building, Glasgow Royal infirmary) in a fasted state at approximately 9.00 am. Participants will be instructed to lie supine on the couch, with the head resting on the pillow provided. Resting metabolic rate will be measured for 20 minutes and fasting blood sample will be obtained. A breakfast meal will be consumed immediately after the fasting sample and a lunch meal after 4 hours. Blood samples will be taken throughout a cannula hourly after breakfast and lunch consumption. Following each blood sample, metabolic rate will be measured for the duration of 20 minutes. Prior each blood sample, participants will fill in appetite questionnaires. Blood samples will be analysed for plasma lipids, glucose, insulin, inflammatory markers and gut appetite hormones using standard existing procedures.
Feacal sample collection & analysis: A disposable stool sample collection kit will be provided prior to the 7-hour trial day. Once collected, the container is sealed and placed in a larger sealable bag with a reducing sachet to remove oxygen and maintain anaerobic bacteria. Stool samples will be measured for changes in gut microbiota based on 16S rRNA amplicon sequencing, bacterial functional capacity and targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia).
Exercise Training Programme: Exercise training will consist of 4 weekly sessions of endurance type exercise (cycling and running) lasting for 30, 40, 50, 60 minutes in the week 1, 2, 3 and 4 respectively. The time and day of each training trial will be agreed between the investigator and the participant and will be based around the participant's availability. All exercise sessions will be supervised by a researcher.
Submaximal Exercise Test: Participants will exercise on treadmill at gradually increasing intensities until 85% of maximal heart rate. During the last minute of each of the intensities heart rate will be measured and expired air will be collected by Douglas bag technique and analysed for oxygen consumption and carbon dioxide production. Relation between heart rate and rate of oxygen consumption will be used to predict maximal oxygen consumption, a marker of cardio-respiratory fitness.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Glasgow, Royaume-Uni, G312ER
- Recrutement
- School of Medicine, University of Glasgow / New Lister Building, Glasgow Royal Infirmary
-
Contact:
- Eleni Rizou, BSc MSc
- E-mail: e.rizou.1@research.gla.ac.uk
-
Contact:
- Konstantinos Gerasimidis, BSc MSc PhD
- E-mail: Konstantinos.Gerasimidis@glasgow.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy, sedentary females, BMI>25 kg/m2, on a stable body weight for the last 3 months
Exclusion Criteria:
- Acute or chronic illness, use of antibiotics the past 3 months, smoking
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Exercise
4-week moderate intensity exercise programme
|
4-week moderate intensity exercise programme
|
|
Aucune intervention: Control
4 weeks of habitual life style
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Gut microbiota composition
Délai: 12 months
|
Changes in the gut microbiota composition measured by 16S rRNA amplicon sequencing.
|
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Interleukin-6 (IL-6)
Délai: 3 months
|
Changes in fasting and postprandial interleukin-6 pre- and post-interventions measured by Human IL-6 ELISA Ready-Set-Go (Affymetrix, eBioscience)
|
3 months
|
|
Glucose
Délai: 3 months
|
Changes in fasting glucose pre- and post-interventions measured by Randox Glucose
|
3 months
|
|
Triglycerides
Délai: 3 months
|
Changes in fasting and postprandial triglycerides pre- and post-interventions measured by Randox Triglycerides
|
3 months
|
|
Insulin
Délai: 3 months
|
Changes in fasting insulin pre- and post-interventions measured by Mercodia Insulin ELISA
|
3 months
|
|
Peptide YY (PYY)
Délai: 12 months
|
Changes in fasting and postprandial peptide YY pre- and post-interventions measured by Human PYY (Total) ELISA (Merc Millipore)
|
12 months
|
|
Glucagon-like peptide-1 (GLP-1)
Délai: 12 months
|
Changes in fasting and postprandial glucagon-like peptide-1 pre- and post-interventions measured by GLP-1 Total ELISA (Merc Millipore)
|
12 months
|
|
Subjective appetite
Délai: 12 months
|
Changes in subjective appetite (hunger, satiety, fullness, prospective food consumption, desire to eat) pre- and post-interventions measured by Visual Analogue Scales (VAS) where respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (minimum score is 0 and maximum score is 100)
|
12 months
|
|
Faecal short-chain fatty acids
Délai: 12 months
|
Changes in concentrations of feacal short-chain fatty acids pre- and post-interventions measured by TRACE 2000 Gas Chromatography (ThermoQuest Ltd)
|
12 months
|
|
Faecal pH
Délai: 1 month
|
Changes in feacal pH between pre- and post-intervention measured by Hanna HI 98140
|
1 month
|
|
Body weight
Délai: 1 month
|
Differences in body weight (kilograms) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Height
Délai: 1 month
|
Height (meters) measured by stadiometer, a vertical ruler with a sliding horizontal paddle which is adjusted to rest on the top of the head
|
1 month
|
|
Body fat (kilograms)
Délai: 1 month
|
Differences in body fat expressed in kilograms between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Body fat (% percentage)
Délai: 1 month
|
Differences in body fat expressed as percentage (%) (proportion of fat to the total body weight) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Body Mass Index (BMI)
Délai: 1 month
|
Differences in body mass index (weight and height will be combined to report BMI in kg/m^2) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
|
Dietary Intake
Délai: 6 months
|
Energy intake and macro nutrient intake using WinDiets software based on food composition tables
|
6 months
|
|
Maximum Oxygen Consumption
Délai: 2 weeks
|
Maximum Oxygen Consumption (ml/kg/min) measured before and after the interventions by Servomex Gas Analyser
|
2 weeks
|
|
Energy substrate oxidation
Délai: 6 months
|
Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (Oxycon Pro)
|
6 months
|
|
Resting Metabolic Rate
Délai: 2 month
|
Resting metabolic rate was measured before and after the interventions (Oxycon Pro)
|
2 month
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Konstantinos Gerasimidis, BSc MSc PhD, University of Glasgow
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 200140132
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Surpoids et obésité
-
Ivoclar Vivadent AGComplétéCaries Pit and Fissure Limité à l'émailAllemagne, Suisse
-
Mathematica Policy Research, Inc.Boston Children's Hospital; Department of Health and Human ServicesPas encore de recrutementIntervention précoce, éducation (Head Start et Early Head Start Access and Participation)États-Unis
-
Bambino Gesù Hospital and Research InstituteComplétéObésité pédiatrique sévère (IMC > 97° pc -Selon les Centers for Disease Control and Prevention BMI Charts-) | Tests de la fonction hépatique altérée | Intolérance glycémiqueItalie
-
Tanta UniversityActif, ne recrute pasPerte osseuse, alvéolaire | Ridge Augmentaton and Dental ImplantsEgypte
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecrutementCarcinome épidermoïde de la tête et du cou | Stage IV Head and Nou Cartane cutané CARCINOMA SELLES A AJCC V8 | Stade III Tête et cou CARCINOME SPÉLIQUE CUDAME AUJCC V8 | Étape I tête et cou cutané cutané carcinome squameux AJCC V8 | Stage II CARCINOME SPÉLÉE CURTANÉE II A AJCC V8États-Unis
-
AstraZenecaActif, ne recrute pasAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerÉtats-Unis, France, Royaume-Uni, Corée du Sud
-
NRG OncologyNational Cancer Institute (NCI)SuspenduCarcinome oropharyngé de stade clinique III médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé de stade clinique IV médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé de stade III (p16-négatif) AJCC v8 | Carcinome oropharyngé de stade IV (p16-négatif) AJCC v8 | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Hong Kong, Suisse, Irlande
-
National Cancer Institute (NCI)SuspenduStage IV Head and Nou Cartane cutané CARCINOMA SELLES A AJCC V8 | Stade III Tête et cou CARCINOME SPÉLIQUE CUDAME AUJCC V8 | Carcinome épidermoïde des paupières | Carcinome épidermoïde acantholytique de la peau | Carcinome épidermoïde à cellules claires de la peau | Carcinome lymphoépithélial... et d'autres conditionsÉtats-Unis, Australie, Canada
-
National Cancer Institute (NCI)RecrutementCarcinome épidermoïde récurrent de la tête et du cou | Carcinome épidermoïde hypopharyngé récurrent | Carcinome épidermoïde laryngé récurrent | Carcinome épidermoïde récurrent de la cavité buccale | Carcinome épidermoïde oropharyngé récurrent | Carcinome épidermoïde métastatique de la tête... et d'autres conditionsÉtats-Unis
-
National Cancer Institute (NCI)Actif, ne recrute pasCarcinome épidermoïde récurrent de la tête et du cou | Carcinome épidermoïde hypopharyngé récurrent | Carcinome épidermoïde laryngé récurrent | Carcinome épidermoïde métastatique de la tête et du cou | Carcinome oropharyngé de stade clinique IV médié par le VPH (p16 positif) AJCC v8 | Carcinome... et d'autres conditionsÉtats-Unis